New research suggests that people who discontinue new weight-loss injections like semaglutide or tirzepatide can put back on reduced body mass far faster than those who stop conventional diet and exercise plans.
Research printed in a prominent medical journal shows that while obese individuals frequently drop a large proportion of their body weight while using the jabs, the weight is regained at an average rate of nearly a kilo each month once they quit.
"People purchasing such drugs should be informed of the danger of fast rebound weight gain when the medication is stopped," cautioned expert Dr. Susan Jebb.
That rate of recovery suggests a reversion to starting weight in about a year and a half.
Weighing Treatments
The study, which examined 37 of studies involving over 9,000 of participants, contrasted the outcomes of GLP-1 agonists with older methods.
Researchers point out that individuals who lose weight through lifestyle changes alone usually see a slower creep back—perhaps 100 grams monthly—once they finish.
Understanding the Fast Rebound
Doctors propose the way of the jabs explains the accelerated rebound.
GLP-1 drugs copy a body's own chemical called glucagon-like peptide-1, which moderates feelings of fullness.
"Artificially providing the hormone concentrations far above than the body's typical production may cause the body to produce less of its own natural GLP-1, and may also reduce responsiveness to its actions," explained Dr. Adam Collins, a dietetics expert.
"Withdrawal of this medication means appetite is unsuppressed, making overeating a significant risk."
An Ongoing Issue?
Medical guidelines recommend the jabs for individuals with obesity-related medical conditions, alongside prescribed lifestyle changes.
Many experts say that, due to the significant potential of weight regain, the therapy should be considered life-long.
This view is supported by drug manufacturers, who say that the findings "highlight the long-term nature of obesity," similar to managing conditions like hypertension.
Patient Testimonies
Users who have discontinued the jabs explain a sudden return of appetite.
"I experienced a trigger that goes on and I was suddenly ravenous," said one woman.
This challenge is worsened if patients have not adopted permanent lifestyle or habit changes during treatment.
Significant Adoption
Recent estimates show that a significant number of people in the UK have used weight-loss jabs in the last 12 months, with desire continuing to grow.
- Adoption is greater among women compared to men.
- The 40s and 50s age group shows the highest usage rates.
- A large proportion access the drugs through private prescriptions rather than the NHS.
Ultimately, researchers stress that while GLP-1 drugs are powerful tools for weight loss, they are not a magic cure and lasting health benefits relies on integrated lifestyle management.
